Dr. Sarah Pearlstein is a fellowship-trained endocrine surgeon and a board certified general surgeon who is passionate about improving the lives of her patients through patient-centered care. Originally from Arizona, she attended Princeton University for undergraduate studies, concentrating in anthropology and linguistics prior to attending medical school at the University of Arizona in Phoenix where she obtained her MD. She then completed her general surgery residency at Lenox Hill Hospital in New York City. She pursued further sub-specialty training at the University of California-San Francisco in endocrine surgery. Her professional interests include the medical and surgical management of thyroid and parathyroid disease. Having been on the patient family side of severe recurrent parathyroid disease, she understands how patients and their families experience the medical and surgical care of endocrine disease and how much a caring surgeon can help. She is dedicated to providing excellent and compassionate care to her patients.
Undergraduate & Graduate
Princeton University: 2011
University of Arizona College of Medicine: 2015
Lenox Hill Hospital: 2020
General Surgery Residency
University of California San Francisco: 2021
Endocrine Surgery Fellowship
Vassar Brothers Medical Center
Pearlstein S, Kuo J, Chabot J, Lee J. “Periadrenal Fat Volume and Waist Measurements are Better Predictors of Prolonged Operative Time in Laparoscopic Retroperitoneal Adrenalectomy than BMI.” World Journal of Surgery. December 2019. PMID: 31820058.
Pearlstein S, Salerno M, Chabot J, Lee J, Kuo J. “Racial and Socioeconomic Disparities in Access and Utilization of Adrenal Metastasectomy.” World Journal of Surgery. October 2019. PMID: 31583457.
Menut K, Pearlstein S, Conroy P, Roman S, Shen W, Gosnell J, Sosa JA, Duh Q-Y, Suh I. “Screening for primary aldosteronism in the hypertensive obstructive sleep apnea population is cost-saving.” Surgery. July 2021. PMD: 34238603.
Lee J, Pearlstein S. “Advances in Diagnosis and Management of Primary Hyperparathyroidism due to Multiple Endocrine Neoplasia (MEN) type 2 Syndrome” Treatment and Management of Endocrinopathies. Elsevier; 2019.
Pearlstein S, Menut K, Duh Q-Y. “Decreased Autofluorescence in a Case of Parathyroid Carcinoma.” VideoEndocrinology. June 2021. https://www.liebertpub.com/doi/abs/10.1089/ve.2021.0011
Pearlstein S, Lahouti A, Opher E, Nikiforov Y, Kuriloff D. Thyroseq V3 molecular profiling for tailoring the surgical management of hurthle cell neoplasms. Case Rep Endocrinol. 2018. PMID: 30105107